Lipoatrophy associated with the use of insulin analogues: A new case associated with the use of insulin glargine and review of the literature

Expert Opinion on Drug Safety

Volumn 9, Issue 2, 2010, Pages 225-231

  Holstein, Andreas ^a   Stege, Helger ^a   Kovacs, Peter ^b  

^a Lippe Detmold Clinic   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Diabetes; Glargine; Insulin; Insulin analogues; Lipoatrophy

Indexed keywords

ANTIRETROVIRUS AGENT; CROMOGLYCATE DISODIUM; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; ANTIDIABETIC AGENT; GLARGINE; INSULIN; LONG ACTING INSULIN;

ADULT; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; CONTINUOUS INFUSION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INJECTION SITE; INSULIN DEPENDENT DIABETES MELLITUS; LIPOATROPHY; PATHOGENESIS; REVIEW; RISK FACTOR; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DIABETES MELLITUS, LIPOATROPHIC; DIABETES MELLITUS, TYPE 1; LIPODYSTROPHY;

ADULT; DIABETES MELLITUS, LIPOATROPHIC; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; LIPODYSTROPHY;

EID: 77649140319     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903496402     Document Type: Review

References (29)

1. Reeves WG, Allen BR, Tattersall RB. Insulin-induced lipoatrophy an immune pathogenesis. Brit Med J 1980;1500-1503 . Provides a detailed overview of histological changes associated with insulin-induced lipoatrophy.
2. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993;16(Suppl 3):155-165
3. Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy: An old complication, a new cause? Diabetes Care 2001;24:174
4. Ampudia-Blasco FJ, Hasbum B, Carmena R. A new case of lipoatrophy with lispro insulin in insulin pump therapy: Is there any insulin preparation free of complications? Diabetes Care 2003;26:953-954
5. Arranz A, Andia V, López-Guzmán A. A case of lipoatrophy with Lispro insulin without insulin pump therapy. Diabetes Care 2004;27:625-626
6. Al-Khenaizan S, Al Thubaiti M, Al Alwan I. Lispro insulin-induced lipoatrophy: A new case. Pediatr Diabetes 2007;8:393-396
7. Hussein SF, Siddique H, Coates P, Green J. Lipoatrophy is a thing of the past, or is it? Diab Med 2007;24:1470-1472
8. Del Olmo MI, Campos V, Abellán P, et al. A case of lipoatrophy with insulin detemir. Diabetes Res Clin Pract 2008;80:e20-21
9. Ampudia-Blasco FJ, Girbes J, Carmena R. A case of lipoatrophy with insulin glargine. Diabetes Care 2005;28:2983
10. Dziura M, Wasikowa R. Lipoatrophy after nuse of long acting insulin glargine analogue in a 32-year-old patient with type 1 diabetes. Pediatr Endocrinol Diabetes Metab 2008;14:61-63
11. Szypowska A, Skórka A, Pańkowska E. Lipoatrophy associated with rapid-acting insulin analogues in young patients with type 1 diabetes mellitus. Pediatr Endocrinol Diabetes Metab 2008;14:117-118
12. Radermecker RP, Pierard GE, Scheen AJ. Lipodystrophy reactions to insulin: Effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol 2007;8:21-28
13. Atlan-Gepner C, Bongrand P, Farnarier C, et al. Insulin-induced lipoatrophy in type I diabetes. A possible tumor necrosis factor-alpha-mediated dedifferentiation of adipocytes. Diabetes Care 1996;19:1283-1285
14. Murao S, Hirata K, Ishida T, Takahara J. Lipoatrophy induced by recombinant human insulin injection. Intern Med 1998;37:1031-1033
15. Mu L, Goldmann JM. Human recombinant DNA insulin-induced lipoatrophy in a patient with type 2 diabetes mellitus. Endocr Pract 2000;6:151-152
16. Beltrand J, Guilmin-Crepon S, Castanet M, et al. Insulin allergy and extensive lipoatrophy in child with type 1 diabetes. Horm Res 2006;65:253-260
17. Ramos AJ, Farias MA. Human insulin-induced lipoatrophy: A successful treatment with glucocorticoid. Diabetes Care 2006;29:926-927
18. Lopez X, Castells M, Ricker A, et al. Human insulin analog-induced lipoatrophy. Diabetes Care 2008;31:442-444
19. Radermecker RP, Scheen AJ. Allergy reactions to insulin: Effects of continuous subcutaneous insulin infusion and insulin analogues. Diabetes Metab Res Rev 2007;23:348-355
20. Fineberg NS, Fineberg SG, Anderson JH, et al. Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996;45:1750-1754
21. Holmberg H, Mersebach H, Kanc K, Ludvigsson J; Insulin Aspart Study Group on Immunogenicity. Antibody response to insulin in children and adolescents with newly diagnosed Type 1 diabetes. Diabet Med 2008;25:792-797
22. Lindholm A, Jensen LB, Home PD, et al. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002;25:876-882
23. Goykhman S, Drincic A, Desmangles JC, Rendell M. Insulin Glargine: A review 8 years after its introduction. Expert Opin Pharmacother 2009;10:705-718
24. Kuerzel GU, Shukla U, Scholtz HE, et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003;19:34-40
25. Chantelau E, Reuter M, Schotes S, Starke AA. Severe lipoatrophy with human insulin: Successfully treated by CSII. Diabet Med 1993;10:580-581
26. Roper NA, Bilous RW. Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro (Humalog). Diabet Med 1998;15:1063-1064
27. Burgdorf WH, Plewig G, Wolff HH, Landthaler M, editors. Braun-Falco's dermatology. 3rd editon, Springer; 2009
28. Herranz P, De Lucas R, Pérez-España L, Mayor M. Lipodystrophy syndromes. Dermatol Clin 2008;26:569-578
29. Moreno S, Miralles C, Negredo E, et al. Disorders of body fat distribution in HIV-1-infected patients. AIDS Rev 2009;11:126-134